Zolbetuximab plus chemo before stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of stomach or gastroesophageal junction cancer that has not spread to distant organs and is considered stage 3 or 4 (T3-4/N0 or T2-4/N+).
- Your tumor must test positive for a protein called CLDN18.2 (at least 75% of cells).
- You must be 19 years or older and in fairly good health (able to walk and do light activity without help).
- Your kidney, liver, and blood counts must be within certain safe limits before starting treatment.
- You cannot have had major surgery within the past 28 days, active infections, or other serious health conditions like heart failure or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.